YOLFTbeta
Sandoz Group AG

Sandoz Group AG

SDZ · SW · Healthcare / Drug Manufacturers - Specialty & Generic

84.60CHF-2.30 (-2.65%)

Price History

Full chart

Market Stats

Previous Close86.90
Open86.70
Day Range84.60 – 86.70
52-Week Range51.91 – 85.62
Volume875.13K
Market Cap36.08B
P/E (TTM)70.66
Forward P/E22.03
EPS1.18
Dividend Yield0.96%
Beta0.40
50-Day Avg73.47
200-Day Avg68.04

About

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Richard Saynor
  • Employees20.00K
  • HeadquartersCentralbahnstrasse 4, Basel, Switzerland, 4051, Switzerland
  • Websitehttps://www.sandoz.com

Leadership

  • Mr. Richard SaynorChief Executive Officer · b. 1967
  • Mr. Remco J. SteenbergenChief Financial Officer · b. 1968
  • Mr. Asaf GalChief Technology Officer · b. 1969
  • Ms. Claire D'Abreu-HaylingChief Scientific Officer & President of Generics Development · b. 1964
  • Mr. Craig MarksHead of Investor Relations
  • Ms. Ingrid SollererGeneral Counsel & Chief Compliance Officer · b. 1974
  • Ms. Tripti JhaChief People Officer · b. 1977
  • Dr. Glenn A. Gerecke Ph.D.Chief Manufacturing & Supply Officer · b. 1959
  • Ms. Rebecca GunternChief Commercial Officer · b. 1972
  • Ms. Keren HaruviPresident of North America · b. 1980

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue9.56B9.68B8.86B9.98B9.12B11.16B
Growth (%)-+1.28%-8.46%+12.64%-8.60%+22.32%
Cost of Revenue4.60B4.63B4.71B5.42B5.46B5.87B
Gross Profit3.95B4.20B4.15B4.56B4.93B5.28B
Gross Margin41.31%43.35%46.87%45.74%54.01%47.36%
Operating Expense2.53B2.70B4.15B4.19B4.62B3.86B
Operating Income1.42B1.49B-22.50K375.00M307.00M1.43B
Operating Margin14.83%15.43%-0.00%3.76%3.37%12.77%
EBITDA1.40B1.76B-22.50K857.00M727.45M2.26B
EBITDA Margin14.63%18.14%-0.00%8.59%7.98%20.28%
Net Income409.01M828.37M-22.86K77.00M1.00M957.48M
Net Income Margin4.28%8.56%-0.00%0.77%0.01%8.58%
R&D866.64M831.11M795.57M926.00M958.00M1.10B
R&D as % of Total Revenue9.07%8.59%8.98%9.28%10.50%9.86%
Interest Expense73.46M64.33M84.05M202.00M235.14M220.00M
Interest Expense % of Total Revenue0.77%0.66%0.95%2.02%2.58%1.97%

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets15.86B15.98B17.56B19.43B19.91B22.03B
Total Liabilities9.04B8.55B8.80B10.78B11.74B12.65B
Total Equity6.82B7.43B77.14K7.28B8.16B9.38B
Cash34.47M36.45M100.00K1.11B1.19B1.74B
Total Debt298.78M284.28M309.02M4.55B4.85B5.68B
Net Debt264.30M247.83M308.92M3.44B3.66B3.94B

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.03B1.24B1.22B362.00M656.00M1.59B
Investing Cash Flow-514.36M-631.76M-430.00M-614.00M-740.00M-980.00M
Financing Cash Flow-513.42M-600.67M-769.00M1.24B242.00M-197.00M
Capital Expenditure309.74M382.16M407.81M567.95M596.00M784.00M
Free Cash Flow720.86M855.75M760.23M-242.64M60.00M810.00M
Dividends Paid----215.00M315.00M
FCF to OCF69.95%69.13%62.16%-67.03%9.15%50.82%
Dividend Paid to FCF----358.33%38.89%

Earnings

Report DateMar 4, 2025Aug 7, 2025Dec 31, 2025Feb 17, 2027Feb 25, 2027
EPS Estimate0.00----
EPS Actual-0.350.871.24--
Surprise-----
Timing-After-hours-After-hoursPre-market

Key Statistics & Ratios

Market Cap36.08B
Enterprise Value40.61B
Trailing P/E70.66
Forward P/E22.03
PEG Ratio1.29
Price / Sales3.09
Price / Book4.95
EPS1.18
Book Value17.06
Revenue (TTM)11.68B
Gross Profit (TTM)5.58B
EBITDA1.57B
Profit Margin5.53%
Operating Margin5.24%
Return on Equity7.25%
Return on Assets3.05%
Shares Outstanding432.69M
Shares Float416.44M
Beta0.40
Dividend Yield0.96%
Dividend Rate0.80
Payout Ratio64.61%

Dividends

20261×
0.80Apr 13, 2026
20251×
0.60Apr 17, 2025
20241×
0.45May 3, 2024